ArticleScientific reports2025
Association between Epstein Barr virus and Oral Lichen Planus clinical phenotypes and p53 expression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Autoimmune Oral Mucosal Diseases in Older Patients: An Overview of Early Recognition and Management in the Primary Care Setting.Geriatrics (Basel, Switzerland) · 2026Review
- Epstein-Barr virus and oral health: epidemiology, pathogenesis, clinical aspects, and diagnostic insights: a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To investigate the association between Epstein Barr virus (EBV) and Oral Lichen Planus (OLP) in both of its clinical phenotypes (erosive and non-erosive), 33 OLP cases divided into erosive and non-erosive phenotypes, and 26 non-OLP cases were evaluated for the presence of EBV using In Situ Hybridization. Immunohistochemistry was used to assess expressions of CD3, CD20, CD138 and p53 in both OLP clinical phenotypes. EBV was detected in 11 (33%) of the OLP cases and none of the non-OLP cases (p = 0.002). CD3 and CD20 were both over-expressed in all OLP cases, however CD138 was significantly over-expressed in the erosive OLP phenotype by comparison to the non-erosive one (p = 0.003), suggesting a possible role of plasma cell in erosive OLP. There was no association between EBV and CD-138, nor with erosive OLP. Interestingly however, EBV had an association with p53 expression among OLP cases (p = 0.038), inferring a role of EBV in possible neoplastic changes in OLP. There appears to be a potential role of EBV in causing at least some OLP cases, regardless of whether OLP is erosive or not. EBV might have an etiological role in causing some OLP cases. This could explain why some OLP cases are recalcitrant to corticosteroids treatment. Clinical trials are needed to establish whether EBV-infected OLP cases respond to antiviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.